Vendor Intelligence Report: ZLZ Peptide

Published 3 Jul 2026. 30-page investigative report on who is behind ZLZ Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 253 Finnrick lab tests, ZLZ Peptide’s overall pass rate is 81% (204 pass / 48 fail). The lab record is uneven rather than uniformly bad: Retatrutide and Tirzepatide are the more defensible core of the catalog, while TB-500 and Tesamorelin sit at the weak end. Under stricter purity and fill assumptions, that separation remains the safer way to read ZLZ.

The non-lab record is more troubling than ZLZ’s best peptide scores. ZLZ-facing pages point to Zhuzhou Lusong Zhongtuo Chemical Technology City; the strongest supplied metadata then carries that retail identity toward Hunan Aslsen Technology Co., Ltd. A CPHI profile for Hunan Aslsen markets BMK and PMK precursor products, a counterparty-risk flag that does not prove contamination but raises the documentation bar for an injectable vendor.

That bar is not met in the public record reviewed. Domain and archive records undercut the site’s longer-history footer; no public GMP/ISO audit, named quality officer, or shareholder trail was located. The complaint file includes an altered-certificate dispute in which a Janoshik task number reportedly failed verification and the buyer was blocked, plus forum moderation labels that moved beyond ordinary skepticism.

Commercially, ZLZ also operates through aliases, WhatsApp/Telegram-style sales, irreversible payment rails, and a referral-credit channel tied to a forum tester. Lookalike domains add a separate impersonation hazard, making official-channel verification part of the product risk rather than an afterthought.

Inside the full report:

  • Product-by-product Finnrick pass/fail rates, rating trajectories, and methodology-divergence charts for all 10 products
  • Corporate-identity exhibits for ZLZ-facing pages, Zhuzhou Lusong, Hunan Aslsen, and B2B platform records
  • CPHI captures of BMK/PMK precursor listings and the report’s quality-system implications
  • Domain, hosting, SSL, and Wayback timeline analysis for zlzpeptide.com
  • Forum/document-integrity exhibits covering GLP-1 Forum moderation, a COA verification dispute, and ThinkSteroids referral disclosure
  • Payment-rail and lookalike-domain analysis covering crypto transfers, WhatsApp/Telegram channels, and copycat domains

Risk assessment

  • Product-quality risk on specific peptides — high: TB-500 31.2%, Tesamorelin 43.07%, CJC-1295 46.28%, BPC-157 47.58%, and Sermorelin 53.13% are materially weaker than ZLZ's Retatrutide, Tirzepatide, and GHK-Cu record.
  • Document-integrity and COA-verification risk — high: GLP-1 Forum documented an Altered Test Certificate incident where a Janoshik task reportedly failed verification and the buyer was blocked; ZLZ accounts were labelled untrustworthy or banned.
  • Controlled-precursor operator risk — high: Records link ZLZ to Hunan Aslsen, whose CPHI profile lists BMK and PMK precursor products; no public GMP, ISO, or independent facility audit was located.
  • Buyer recourse and payment risk — high: ZLZ product-page terms list USDT, Bitcoin, Western Union, MoneyGram, and bank transfer, with no card, PayPal, escrow, or chargeback path found.
  • Copycat and official-channel verification risk — high: Reddit users reported zlz-peptides.com as a non-delivery scam and zlzpeptides.com as separate or unclear; no public authorized-rep, reseller, or anti-counterfeit verification list was found.
  • Affiliate-promotion risk — medium: Meso-Rx records show a tiered referral-credit program through Marina; X/web scans found limited public code activity, but informal incentives can bias batch reports.
  • Corporate ownership and personnel transparency risk — medium: Public records identify Zhuzhou Lusong and Hunan Aslsen leads, but no directors, shareholders, or natural-person owners; sales occur through aliases including Mia, Jessie, Vivian, Amy, and Marina.